Recently, several reports have demonstrated that there are substantial discordances in hormone receptor expression and HER-2 status between primary tumors and metastases, which could alter the treatment and prognosis of recurrent breast cancer [1-5]. This evidence concerns the gene NR4A1 and breast cancer.